Sotira has announced the successful completion of the second phase of pre-clinical testing for its COVID-19 therapeutic and vaccine-alternative, KEPTIDE™ COVID, confirming this molecular therapy completely prevented the entry of SARS-CoV2 in the lungs and kidney. This latest study was tested on humanized K18-hACE2 mice. These mice express human ACE2, the receptor used by the virus to gain entry to cells. The Sotira scientific team also found that the intranasal treatment of KEPTIDE™, 30 minutes before viral administration, not only protects injuries in lungs and kidney, but also prevents acute death response in these humanized mice.
Sotira also collaborated with CDC-approved Coppe Laboratories to successfully complete their virus study in a BSL-3 environment.
"When the pandemic struck, we wanted to craft a targeted intervention that, unlike a vaccine or existing medical treatment, was specifically designed to prevent the virus from attaching to ACE-2 receptors in your mid-respiratory area," Dr. Gottschalk, said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
- KEPTIDE™ acts as a blocker that protects the receptor cells in the human body that serve as a gateway for COVID-19.
- KEPTIDE™ targets the cells in the human body most at risk for infection vs. targeting the virus which continues to mutate in unpredictable ways.
- The design of KEPTIDE™ and its microscopic size prevent it from altering the normal function of these critical receptor cells.
- The ingredients of KEPTIDE™ are currently used in many therapeutic domains and animal studies have shown absolutely zero toxicity.
- It is equally effective for the most at-risk populations, including the elderly and the immunocompromised.
- This blocking mechanism prevents the spread and infection of the virus into the rest of the body.